Fundraising FoxOxford Investment Opportunity Network (OION) — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Argonauteargonauterna.cominSep 2026
Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise.
BiotechDeep TechDigital HealthHealthtechCardiff, GB
Anthony Parker(Co-founder)inRichard Tompkins(Co-founder)inMike Khan(CEO)in
BoardJohnathan Vincent Matlock(Director)David William Dawson Ball(Director)Alexander Michael Fink(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.